Background: Spirometry forms the foundation investigation for the diagnosis and mon-
Introduction
Spirometry, the most commonly performed lung function test, provides an objective measure for the determination of airflow obstruction and the assessment of therapeutic intervention. Spirometry is an established tool in the diagnostic workup of chronic obstructive pulmonary disease (COPD) and asthma. 1, 2 Interpretation strategies for airflow obstruction using spirometry advised by local and international societal practice guidelines vary, leading to a lack of standardisation in diagnosis of airflow obstruction. For example, the American Thoracic Society/European Respiratory Society (ATS/ERS) lung function interpretative strategies document 3 and the Australian Asthma Handbook (AAH) 4 define airflow obstruction as forced expiratory volume in 1 s/forced vital capacity (FEV 1 / FVC) less than the lower limit of the normal range (<LLN), where LLN is defined as the 5th percentile, or 1.64 standard deviations (SD) below the mean predicted value (−1.64 z-scores). Comparatively, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) practice guideline Australian and New Zealand management guidelines for COPD, 7 define airflow obstruction as FEV 1 /FVC <0.70 -that is, they use a fixed cut-off criterion as the LLN. The Global Initiative for Asthma (GINA) guidelines advocates use of a fixed cut-off of FEV 1 / FVC <0.75-0.80 to define airflow obstruction. 8 Similarly, the definition of a significant bronchodilator response to assess reversibility of airflow obstruction varies between guidelines. The ATS/ERS 3 defines a significant bronchodilator response as an increase in FEV 1 and/or FVC ≥200 mL and ≥12%, while the GOLD, COPD-X, AAH and GINA practice guidelines define a significant bronchodilator response as an increase in FEV 1 only of ≥200 mL and ≥12%. [4] [5] [6] [7] [8] The choice of spirometry reference equations is also important as they are used to determine the lower limit of normal and need to reflect the demographic of the population being tested. In 2016, the Australian and New Zealand Society of Respiratory Science (ANZSRS) published a position statement 9 identifying the 2012 Global Lung Initiative (GLI 2012) multi-ethnic spirometry reference equations 10 as the reference equations of choice for use in Australia and New Zealand. This position statement received endorsement from the Thoracic Society of Australia and New Zealand (TSANZ). The position statement also advocated the use of lower limits of normal using the 5th percentile, rather than fixed cut-offs.
Variation in spirometry interpretation practices for defining airflow obstruction in Australia and New Zealand have not previously been reported. In 2016, an audit was conducted seeking to identify current TSANZ accredited complex lung function laboratories' testing and interpretation practices in Australia and New Zealand. This paper reports on survey questions pertinent to spirometry interpretation for airflow obstruction, with an emphasis on choice of spirometry reference equations, defining the lower limit of normal, parameters used for identifying airflow obstruction, defining airflow obstruction and defining a significant bronchodilator response.
Methods
TSANZ accredited lung function laboratories identified from the TSANZ website (accessed 23 May 2016) were invited to participate in an online survey comprising 33 questions. Invitations were sent to senior respiratory scientists or laboratory directors.
Results from survey questions relevant to laboratory demographics and spirometry interpretation related to airflow obstruction were collated and reviewed. Pertinent survey questions are detailed in Figure 1 .
A certificate of approval by the institutional Ethics Committee was obtained.
Results
Thirty-nine laboratories were invited to participate in the survey. Of these, 36 laboratories provided complete responses to all questions and were included in subsequent analysis. Of the remainder, two laboratories provided incomplete responses, and one declined to participate.
Respondent demographics
Respondent sites were located as follows: New South Wales: 11; Queensland: 8; Victoria: 7; South Australia: 4; Western Australia: 1; Tasmania: 1; New Zealand: 4. Thirty-five of the 36 respondents were respiratory scientists; the remaining respondent's designation was not identifiable.
Thirty-five laboratories were public facilities and one was private. At a minimum, all respondent laboratories performed spirometry, static lung volumes, carbon monoxide transfer factor and bronchial provocation tests. Laboratories were predominantly adult testing centres (20 adult, 5 paediatric, 11 tested both). Where laboratories tested both adults and paediatric populations (11 laboratories), adults represented the following proportion of encounters: ≥90% in 8, ≥85% in 1 and ≥75% in 2 laboratories. The median number of patient encounters for the year 2015 across all laboratories was 3460 (IQR: 2517-5116).
Spirometry reference equations
Reference equations utilised for spirometry interpretation by respondent laboratories included the GLI 2012 reference equations (16/36), 10 the third National Health and Nutritional Examination Survey (NHANES III) reference equations (8/36), 11 European Community of Coal and Steel (ECCS) reference equations (8/36), 12 Knudson reference equations (2/36), 13 a combination of reference sets (ECCS/NHANES III) (1/36), and a locally derived reference set (1/36).
14 Three laboratories using NHANES III reference equations and one laboratory using ECCS reference equations noted that they were transitioning to GLI in the short term
Defining the lower limit of normal
Twenty-seven of the 36 laboratories defined the LLN using the 5th percentile, 7 of 36 used a fixed cut-off criterion to define the lower limit of normal, and 2 of 36 laboratories used other criteria (LLN and fixed cutoffs, LLN and per cent predicted).
Parameters used to identify airflow obstruction
Of the thirty-six laboratories, 29 utilised Overall, 22 of 36 laboratories defined the lower limit of normal as the 5th percentile, used FEV 1 /FVC as the sole parameter to identify airflow obstruction, and defined airflow obstruction as FEV 1 /FVC <5th percentile in line with international standards. 3 Six laboratories provided conflicting information regarding the definition of the lower limit of normal, the parameters used for identifying airflow obstruction, and the definition of airflow obstruction. For example, two laboratories defined LLN as the 5th percentile, however airflow obstruction was defined using fixed cut-off criterion (FEV 1 /FVC < 0.70); two laboratories used multiple parameters to identify airflow obstruction, however airflow obstruction was defined using FEV 1 /FVC only. Definition of significant bronchodilator reversibility Table 1 shows the number of laboratories that adhere to the different societal or guideline definitions of a significant bronchodilator response with respect to assessing reversibility of airflow obstruction.
Discussion
This study has demonstrated that there is substantial variation in spirometry interpretation practices for assessing airflow obstruction across Australian and New Zealand lung function laboratories. The variation was observed in practices used for defining the LLN, parameters used for identifying airflow obstruction, the criteria used to define airflow obstruction, defining a significant bronchodilator response and choice of reference equations. This discordance existed despite the fact that all laboratories were TSANZ accredited. The observed variation is likely to be amplified when non-accredited testing facilities throughout Australia and New Zealand are taken into account. The variation in practice may translate into clinically appreciable differences for the diagnosis and management of common obstructive respiratory conditions.
Choice of reference equations
Results showed that less than half of the laboratories surveyed were using the GLI 2012 spirometry reference equations 10 as recommended by ANZSRS, 9 although four laboratories using other reference equations were in the process of transitioning to GLI 2012. The NHANES III reference equations 11 were next most commonly used, followed by ECCS reference equations. 12 The ANZSRS recommended use of the GLI 2012 reference equations based on the work of Hall et al. 15 who demonstrated good correlation between 2066 healthy Caucasian, Australasian spirometric data sets and the GLI reference set. It has been shown that large subject numbers (a minimum of 150 male and 150 female participants) are required to validate reliably reference equations against a local population. 16 This is rarely a feasible option for laboratories and hence Hall et al.'s study provides important information on reference equation selection.
A large assessment of the implications of adopting the GLI 2012 reference equations in place of NHANES III or ECCS by Quanjer et al. 17 showed a modest reduction in the detection of a reduced FVC when transitioning from NHANES III to GLI 2012, and a considerable increase in detection of a reduced FVC when transitioning from ECCS to GLI. However, the authors concluded that overall rates of detection of airflow obstruction using the GLI 2012 equations would be similar to both NHANES III and ECCS. This suggests that clinical impact from differences in the detection of airflow obstruction using FEV 1 / FVC <5th percentile between the reference sets of GLI 2012, NHANES III and ECCS would be small.
The ATS/ERS interpretative strategies document of 2005 3 recommended the use of NHANES III reference equations in North America, which may explain its prevalence in Australasian laboratories. It is also worth noting that the NHANES III data set made a substantial contribution to the data set used to determine GLI reference equations so differences between the two sets with respect to detection of abnormalities are not substantial. However, the ATS/ERS 3 recommended against the use of the ECCS reference set in Europe because ECCS reference values have been found to be lower than more recent European reference sets 18 -hence it is unclear why these equations are still being used.
Our study did not extend to asking individual laboratories the important question of why they chose a particular set of equations; however, one laboratory nominated that they utilised a locally developed reference set based on the local population 14 and another laboratory noted that they were limited in their choice of reference equations by the software they use. It is interesting to note that the one laboratory using a local spirometry reference equation set uses a set that does not include a reference values for FEV1/FVC ratio, resulting in an inability to choose to use the ATS/ERS definition of obstruction for interpretation.
Criteria used for the definition of airflow obstruction
This study established that the majority of TSANZ accredited laboratories adhere to the ATS/ERS definition of an obstructive ventilatory defect, FEV 1 /FVC <5th percentile. 3 It is likely that the majority of laboratories use the ATS/ERS definition for airflow obstruction because it is the international standard, and the TSANZ respiratory function laboratory accreditation programme manual recommends laboratories follow the international standards. 19 The reason the other laboratories do not follow the ATS/ERS interpretive strategy remains unclear.
It has been shown that FEV 1 /FVC declines with age in a normal population, and hence the LLN is age-dependent. 10, 20, 21 Using a fixed cut-off to define airflow obstruction may result in under classification of obstruction in the young and over classification in older adults. [22] [23] [24] [25] While GOLD advocates use of a fixed cut-off for 'simplicity and consistency' and because it is 'independent of reference values', 5, 6 others disagree with this approach. 26 In a dedicated lung function laboratory where there is expertise in interpretation, lower limits of normal using the 5th percentile should be used.
Vaz Fragoso et al. 27 looked at classifications of COPD in older people using FEV 1 /FVC <5th percentile and GOLD criteria (FEV 1 /FVC < 0.70) compared to the 5-year cumulative incidence probability of COPD hospitalisation. Of those with normal spirometry using FEV 1 /FVC <5th percentile, 34.6% had airflow obstruction as defined by GOLD. These subjects with discordant classifications had a low probability of COPD hospitalisation, and this probability of hospitalisation was comparable to those with normal spirometry using FEV 1 /FVC <5th percentile or GOLD criteria. Conversely, those with airflow obstruction using FEV 1 /FVC <5th percentile were found to have increased risk of COPD hospitalisation.
A large prospective cohort study of young and middleaged adults concluded an increase in cardiovascular and respiratory morbidity associated with airflow limitation defined according to the LLN but not a fixed cut off ratio of FEV 1 /FVC <0.70. 28 
Reversibility of airflow obstruction
Greater than two-thirds of TSANZ accredited laboratories adhered to the international standard's definition of a significant bronchodilator response (an increase in FEV 1 and/or FVC of ≥200 mL and ≥12%). revealed only 2 of the 37 surveyed laboratories reported a significant bronchodilator response in accordance with the ATS/ERS definition 3 and 1 of 37 laboratories in accordance with the GOLD, GINA, COPD-X and AAH definitions ( Table 2) . [4] [5] [6] [7] [8] While there has been a shift to conformity in the period between the two studies, there were still 10 laboratories that used alternative criteria to define bronchodilator response in the current study.
It is notable that the definition for bronchodilator response in COPD clinical guidelines considers change in FEV 1 only. [5] [6] [7] A significant increase in FVC (≥200 mL and 12%) may be related to a reduction in hyperinflation (reduction in residual volume), which has clinical benefits. Significant increases in FVC following bronchodilator administration have been shown to occur more often than significant increases in FEV 1 in severe COPD. 30 Differences between clinical practice guidelines and the ATS/ERS definitions of BD response may result in inconsistencies in clinical management.
Clinical impact
The variation in definitions of obstruction and bronchodilator response findings is unsurprising, considering the diversity of definitions amongst major guideline groups. It should be noted however that the TSANZ accreditation manual recommends use of the ATS/ERS standards for interpretation of spirometry.
Inconsistent spirometry criteria to define airflow obstruction have been shown to impact on prevalence of diagnosis of COPD. The Burden of Obstructive Lung Disease (BOLD) study demonstrated the use of a fixed cut-off point of FEV 1 /FVC <0.7 lead to a significant overestimate of COPD prevalence (false positives), particularly in adults aged over 52 years. 31 The use of FEV 1 /FVC <5th percentile limits airflow obstruction misclassification. 23 Similarly, discordant definitions of airflow obstruction have been shown to increase misclassification of asthma diagnoses. Use of fixed cut-off criteria of FEV 1 /FVC <0.7 leads to an underestimation of asthma in young adults, while FEV 1 /FVC <0.8 leads to an overestimation of an asthma diagnosis. 32 These findings support the need for further work to standardise the definitions to promote clarity for clinical diagnosis and management.
Limitations
TSANZ accreditation assists to standardise practice by promoting adherence to international standards for the performance and interpretation of spirometry. 33 Only TSANZ accredited laboratories were audited in this study, which may result in sampling bias. Given the persisting variability of spirometry interpretation strategies among TSANZ accredited laboratories throughout Australia and New Zealand, the authors are mindful that variation is likely to be amplified in unaccredited laboratories and primary care settings.
Conclusion
This study has identified substantial variation in spirometry interpretation practices for airflow obstruction amongst TSANZ accredited lung function laboratories.
This variation may be increased taking into account practices of non-accredited laboratories and spirometry performed in primary care.
The discrepancy among major societal guideline groups regarding spirometry interpretation for airflow obstruction indicates best standard practice is yet to be established. A standardised approach to spirometry interpretation of airflow obstruction would limit misclassification and potential mismanagement.
This study highlights a clear need for further education and training to ensure spirometry interpretation practices for airflow obstruction across the Australasian region are standardised. Ongoing discussion regarding a formal standardisation process is required.
